Does ibogaine work for treatment-resistant depression?

The 2023 Stanford study published in Nature Medicine found 87% average reductions in depression symptoms at one month in 30 special operations veterans with documented treatment-resistant depression — people for whom conventional treatment had not worked. The mechanism is distinct from antidepressants: GDNF and BDNF upregulation, NMDA antagonism, and opioid receptor modulation. Whether these results hold long-term and in broader populations is what the current $50 million Texas clinical trials are designed to establish.

How is ibogaine different from antidepressants for depression?

SSRIs and SNRIs work by modulating serotonin or norepinephrine reuptake — they do not directly address GDNF depletion or trigger the BDNF upregulation that ibogaine appears to produce. Ibogaine acts simultaneously on GDNF and BDNF pathways, NMDA receptors, opioid receptors, and the serotonin transporter. The result is a neuroplasticity window lasting weeks to months after a single ceremony. Antidepressants are taken daily and work through ongoing medication effect. They are different models, not variants of the same one.

What does the Stanford ibogaine study show about depression?

The 2023 Stanford study (Williams et al., Nature Medicine) treated 30 special operations veterans with ibogaine at a clinic in Mexico. One month post-treatment, the average reduction in depression symptoms was 87%. For context, conventional antidepressant research considers a 50% reduction a strong response. The population was specifically treatment-resistant — people who had already tried and not responded to conventional treatment. Methodological limitations: 30 participants, no placebo arm, single treatment site. The Texas clinical trials — $50 million USD across UTMB, UTHealth Houston, Texas A&M, and Baylor — are now underway to replicate these findings at scale.

Can I do ibogaine if I am currently taking antidepressants?

Not without a completed, physician-supervised taper first. SSRIs and SNRIs are absolute contraindications for ibogaine — ibogaine inhibits the serotonin transporter, and the combination creates risk of serotonin syndrome, which can be fatal. The taper must be complete and confirmed before any ceremony date is set. The typical timeline is 2–4 weeks, sometimes longer for medications with extended half-lives such as fluoxetine. This is a hard medical requirement, not a preference or a caution to be weighed.

Who is not an appropriate candidate for ibogaine for depression?

Absolute contraindications include: current SSRIs or SNRIs without a completed supervised taper (serotonin syndrome risk — no exceptions); QT prolongation or significant cardiac arrhythmia; bipolar I disorder (risk of triggering mania during the active experience); active psychosis or schizophrenia-spectrum disorder; severe liver or kidney disease; lithium; and pregnancy. Bipolar depression and postpartum depression are not conditions the ibogaine evidence directly addresses. The screening conversation is where individual candidacy is determined.

How long do the antidepressant effects of ibogaine last?

The Stanford study measured at one month and found 87% reductions. The research does not uniformly establish what happens at six or twelve months. Noribogaine — ibogaine's active metabolite — remains pharmacologically active for weeks to months after ceremony, sustaining a neuroplasticity window. Long-term outcomes depend substantially on integration work during that window. People who return to unchanged environments and relationships without structured support typically find the gains diminish faster than those who engage actively with the integration period.

What does ibogaine for depression cost in Canada?

Iboga ceremony at Transcend in Vancouver, BC costs $2,000–$5,000 CAD. This covers an on-site medical professional throughout the 12–24 hour active experience, continuous cardiac monitoring, whole-plant root bark, facilitation, and a 2–3 day supervised recovery period. Integration coaching — $150–$300 CAD per session, with packages of three or more sessions available — is separate and is what most directly determines whether the depression reduction holds. No ceremony date is confirmed before candidacy is established through medical screening.

Is ibogaine or 5-MeO-DMT better for depression?

They address depression through different mechanisms. Ibogaine works through 12–24 hours of autobiographical review — it tends to surface and make accessible the biographical material from which the depression is constructed. 5-MeO-DMT works through 20–45 minutes of ego dissolution — it removes the framework through which depression is maintained, without narrative content. For treatment-resistant depression with identifiable biographical roots, ibogaine is typically the primary consideration. 5-MeO-DMT is often more relevant as a second step after the biographical work has been done. The contraindications for SSRIs are identical for both.

Ibogaine for Depression: What the Research Shows and Who It Is Not For

Ibogaine for depression produces measurable reductions through mechanisms distinct from any antidepressant currently in use. The 2023 Stanford study published in Nature Medicine found 87% average reductions in depression symptoms at one month in 30 special operations veterans with treatment-resistant depression — a population for whom conventional treatment had not worked. The mechanism involves GDNF and BDNF upregulation, NMDA antagonism, and opioid receptor reset. It is not how antidepressants work. And the most common antidepressant in clinical use today — SSRIs — is an absolute contraindication for ibogaine ceremony.

Ibogaine addresses depression through GDNF and BDNF upregulation — neurotrophin proteins responsible for neural repair and plasticity — NMDA receptor antagonism, and opioid receptor modulation. The 2023 Stanford study found 87% reductions in depression symptoms at one month in 30 treatment-resistant veterans. Conventional antidepressant research considers a 50% reduction a strong response.

What Treatment-Resistant Depression Actually Is

Treatment-resistant depression is not a personality type or a failure of willpower. It has a clinical definition: depression that has not responded to at least two adequate antidepressant trials — adequate meaning appropriate dose, appropriate duration, confirmed adherence.

By that definition, an estimated 30% of people diagnosed with major depressive disorder are treatment-resistant. The interventions they cycle through — multiple SSRIs, SNRIs, augmentation strategies, electroconvulsive therapy — address the serotonin and norepinephrine systems, and do so imperfectly. The GDNF pathway, which governs neuronal repair and the sustained health of the prefrontal cortex and limbic system, is not something any current antidepressant directly targets. Ibogaine does.

The people who arrive at iboga ceremony with the strongest results are often the ones who spent years trying everything else first — SSRIs that blunted rather than resolved, therapy that circled without landing, augmentation strategies that held for months, then did not. By the time they arrive, they are not naive about the difficulty of what they are attempting. That scepticism — earned the hard way — tends to produce people who are genuinely ready to encounter what the medicine shows them.

How Ibogaine Works on the Depressed Brain

Ibogaine acts on at least four receptor systems simultaneously. This is not how antidepressants work — which typically target one system and rely on downstream effects to produce mood change.

The most relevant mechanism for depression is GDNF (glial cell line-derived neurotrophic factor) upregulation. GDNF is a neurotrophin — a protein responsible for the survival, repair, and growth of neurons, particularly in the dopaminergic and limbic pathways. Chronic depression depletes GDNF. Ibogaine appears to restore it at levels no current pharmaceutical approaches, as documented in MAPS research summaries on ibogaine pharmacology.

The second mechanism is BDNF (brain-derived neurotrophic factor) upregulation. BDNF governs synaptic plasticity — the brain's ability to form new connections and revise existing ones. Low BDNF is consistently found in people with chronic depression. Ibogaine triggers an acute elevation followed by a sustained period through the noribogaine phase — the active metabolite that remains pharmacologically present for weeks to months after ceremony.

The third mechanism is NMDA receptor antagonism. Ibogaine blocks NMDA receptors — glutamate channels involved in maintaining fixed patterns of thought and mood. This is mechanistically related to how ketamine produces rapid antidepressant effects, though ibogaine's receptor profile is more complex. The fourth involves sigma-2 and serotonin transporter modulation, which appear to contribute to mood regulation during the active experience.

The combined result is a window — beginning during the active ceremony and extending weeks to months afterward — in which existing depressive patterns are less fixed than normal and more accessible to change.

What the Stanford Study Found

The 2023 Stanford study, published in Nature Medicine by Williams et al., is the most cited reference point for ibogaine treatment for depression. The population was 30 special operations veterans with PTSD, traumatic brain injury, and treatment-resistant depression — people who had already tried conventional treatment and not responded adequately.

At one month post-treatment:

Depression symptoms: 87% average reduction
PTSD symptoms: 88% average reduction
Anxiety symptoms: 81% average reduction

The limitations deserve equal statement: 30 participants is not a definitive population. There was no placebo arm. The treatment occurred at a single clinic in Mexico. The authors acknowledge these constraints directly. They are genuine methodological limitations.

The context also deserves statement. Conventional antidepressant research considers a 50% reduction in depression scores a "strong response." The ibogaine data produced 87% — in a population defined by the failure of conventional treatment, not a treatment-naive one. The Texas clinical trials — $50 million USD committed across UTMB, UTHealth Houston, Texas A&M, and Baylor — are now underway to test whether these findings hold at scale and over longer follow-up periods.

Dense old-growth rainforest — the natural habitat of Tabernanthe iboga — Photo via Pexels

The Neuroplasticity Window — and Why It Matters More Than the Ceremony

Ibogaine ceremony is not the treatment. The ceremony initiates a neuroplasticity window — a period in which the brain is more capable of forming new patterns than it normally is. That window is the treatment, and the integration period that fills it determines whether the 87% depression reduction at one month translates into lasting change.

This is not a peripheral point. Integration support is not a bonus service — it determines whether the ceremony produces lasting change. The noribogaine metabolite sustains elevated GDNF and BDNF for weeks to months after ceremony. What a person does during that period — the relational patterns they establish, the professional support they engage, the concrete environmental changes they make — determines how much of the neuroplastic potential is used. People who return immediately to unchanged conditions tend to find the gains do not hold.

The integration coaching programme at Transcend runs for weeks to months after ceremony at $150–$300 CAD per session, with packages of three or more sessions available. It is not required. But the evidence for why it matters is the same evidence that explains why the ceremony works in the first place.

Ibogaine vs Antidepressants

SSRIs and SNRIs work by modulating serotonin or norepinephrine reuptake. They do not address GDNF depletion. They do not trigger BDNF upregulation at the levels ibogaine appears to produce. They do not modulate NMDA receptors.

This is not a dismissal of antidepressants — they are appropriate treatment for many people and work for a significant portion of those who take them. The relevant question for someone with treatment-resistant depression is what antidepressants have not reached, and whether those gaps are specifically what ibogaine addresses. For a meaningful proportion of people who have tried two or more antidepressants without adequate response, the GDNF and BDNF mechanisms are precisely what was not being touched.

The comparison with ketamine is worth stating directly. Ketamine also acts on NMDA receptors and produces rapid-onset antidepressant effects. The differences between ibogaine and ketamine include duration of neuroplastic effect (ibogaine's window is longer), receptor profile breadth (ibogaine acts on more systems simultaneously), and access — ketamine is available within the US healthcare system; ibogaine is not.

What Ibogaine Does Not Do for Depression

Ibogaine is not an antidepressant in the pharmaceutical sense. It is not taken daily and it does not produce effects through ongoing medication. The 87% reduction at one month is the result of a single ceremony followed by integration — a fundamentally different model from SSRIs, and not superior for everyone.

Ibogaine does not address the biological substrate of all depressions equally. People whose depression has a strong hormonal or endocrine component — postpartum depression, thyroid-related depression — are not the target population the evidence addresses. People with bipolar depression are not appropriate candidates for ibogaine ceremony: the stimulating effects during the active phase carry meaningful risk of triggering mania in people with bipolar I.

Ibogaine does not make the experience of depression comfortable during ceremony. The active 12–24 hours involve an extended autobiographical review — a confrontation with the content from which the depression is constructed, not relief from it. The 87% reduction comes after that confrontation, not during it.

And ibogaine ceremony followed by an unchanged life produces limited results. The medicine opens a window. What is done in that window — and what changes in the conditions that produced the depression — determines the outcome. For people who are not in a position to commit to integration, the ceremony alone is not a reliable treatment.

Who Is Not an Appropriate Candidate

Absolute contraindications for ibogaine ceremony include:

Current SSRIs or SNRIs without a completed supervised taper. Ibogaine inhibits the serotonin transporter — the combination with serotonergic medications creates risk of serotonin syndrome, which can be fatal. No exception exists. The taper must be complete before any ceremony date is confirmed.
QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction. Ibogaine extends the QT interval. This is the mechanism behind ibogaine-related deaths. Pre-ceremony EKG is not optional — it identifies this risk before ceremony rather than during it.
Severe liver or kidney disease. Ibogaine is metabolised by the liver. Impaired liver function alters how ibogaine is processed and significantly increases cardiac risk.
Active psychosis or schizophrenia-spectrum disorder. The neurological activation during ibogaine ceremony is contraindicated in the context of psychotic symptoms.
Bipolar I disorder. The stimulating effects of ibogaine during the active phase carry meaningful risk of triggering mania.
Lithium, methadone, or certain other psychiatric medications. Lithium is a cardiac contraindication. Methadone requires a specific transition protocol before ibogaine ceremony can proceed.
Pregnancy.

Some of these are permanent disqualifiers. Others require a preparation period — supervised medication taper, medical stabilisation — before candidacy can be established. The screening process is where that determination is made. We turn people away when the contraindication is present and the risk is real. That conversation is not comfortable. It is also the most important thing we do.

Is This Right for You?

If you have treatment-resistant depression — two or more adequate antidepressant trials without adequate response — and you are not on medications that constitute absolute contraindications, ibogaine ceremony is worth considering seriously. The research is specific and the mechanism addresses what antidepressants have not reached.

If you are currently on SSRIs, the conversation starts with a supervised taper, not a ceremony date. That is a real prerequisite, not an administrative note. The typical timeline is 2–4 weeks, sometimes longer depending on the specific medication and its half-life.

If you have a cardiac history, the conversation starts with a current EKG.

The ceremony page covers what the full programme involves. The FAQ addresses the most common screening questions. If you want to discuss your specific situation, the right step is to submit an application — every application receives a personal response within 2–3 business days. If this is not the right path for you at this time, we will say so directly, and we will say why.